TARA | Protara Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.18 - 4.45
52 Week Range	1.5950 - 10.48
Beta	1.50
Implied Volatility	327.08%
IV Rank	59.01%
Day's Volume	377,155
Average Volume	288,259
Shares Outstanding	36,767,500
Market Cap	156,629,550
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-10-22

Valuation
Profitability
Growth
Health
P/E Ratio	-1.96
Forward P/E Ratio	N/A
EPS	-2.17
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	26
Country	USA
Website	TARA

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

TARA's peers: ATHE, GTBP, PSTV, RANI, SVRA, SYBX, VCNX, MNPR, MIRO, SRZN, IKNA, XLO, SRRK, VACC, MTCR, MGTA, TCON, STSA, LYRA, TRVI, SQZ, URGN, VINC

*Chart delayed

Analyzing fundamentals for TARA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see TARA Fundamentals page.

Watching at TARA technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on TARA Technicals page.